William Sargent Appointed to a Senior VP Position with a Private Pharmaceutical Company

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

September 17, 2020

William Sargent has been appointed Senior Vice President of Venatorx Pharmaceuticals.

William Sargent has over 25 years of biopharmaceutical industry experience, including multiple products and line extension launches. He will be responsible for designing and executing Venatorx’s commercial strategy across its portfolio of clinical and preclinical antibacterial and antiviral programs.

“Will has a proven track record of success and extensive expertise across a wide array of therapeutic areas, most notably in antibiotics,” said Christopher J. Burns, Ph.D., President and CEO of Venatorx. “As we develop our domestic and global go-to-market strategies and competitive analyses for our clinical and preclinical programs, it’s vital to have expertise like Will’s to drive our unique positioning, business intelligence and commercial plans forward.”

Prior to joining Venatorx, Mr. Sargent served as Vice President, Commercial Strategy at Nabriva where he led the launch and commercialization for Xenleta, a novel antibiotic approved for the treatment of community acquired bacterial pneumonia (CABP). Previously, Mr. Sargent held a variety of leadership roles at Auxilium Pharmaceuticals, including Vice President, Orthopedic Business Unit where he led the company’s sales and marketing teams advancing XIAFLEX® for the treatment of Dupuytren’s contracture and development of additional pipeline indications. Before Auxilium, Mr. Sargent was a biotechnology equities analyst at Bank of America and held multiple commercial roles at Amgen and Immunex. Mr. Sargent received his BA in Biology from Johns Hopkins University and an MBA from the University of Washington Foster School of Business.

“As antibiotic resistance continues to reach dangerous levels in the U.S. and around the world, it is an exciting time to join a company that has become a driving force for innovation and transformation in the anti-infective space,” said Mr. Sargent. “Venatorx has a robust portfolio of clinical and preclinical antibacterial and antiviral assets that each have a unique value proposition and potential for long-term health benefits for patients. I’m thrilled to join this dynamic, dedicated team and look forward to leading the company’s strategic commercial plans to foster growth and partnership opportunities for the company and its assets.”



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.